ADVI’s Lindsay Bealor Greenleaf told BioWorld that whether the launch interchangeable insulin biosimilars will result in lower costs for patients will be decided by PBMs.
March 14, 2022, ADVI’s Lindsay Bealor Greenleaf told BioWorld that whether the launch interchangeable insulin biosimilars will result in lower costs for patients will be decided by PBMs. Read the full article here.
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.